| General Information | |
|---|---|
| ZINC ID | ZINC000095573550 |
| Molecular Weight (Da) | 558 |
| SMILES | CC(C)(N/C(=NS(=O)(=O)c1ccc(Cl)cc1)N1C[C@@H](c2ccccc2)C(c2ccc(Cl)cc2)=N1)C(N)=O |
| Molecular Formula | C26Cl2N5O3S1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 144.881 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 8 |
| Heavy Atoms | 37 |
| LogP | 4.989 |
| Activity (Ki) in nM | 8.5114 |
| Polar Surface Area (PSA) | 125.6 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.919 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 18 |
| Fraction csp3 | 0.19 |
| Ilogp | 3.76 |
| Xlogp3 | 4.89 |
| Wlogp | 4.71 |
| Mlogp | 3.65 |
| Silicos-it log p | 4.16 |
| Consensus log p | 4.24 |
| Esol log s | -6.22 |
| Esol solubility (mg/ml) | 0.00034 |
| Esol solubility (mol/l) | 0.0000006 |
| Esol class | Poorly sol |
| Ali log s | -7.26 |
| Ali solubility (mg/ml) | 0.0000305 |
| Ali solubility (mol/l) | 5.46E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.87 |
| Silicos-it solubility (mg/ml) | 0.00000075 |
| Silicos-it solubility (mol/l) | 1.36E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -6.23 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 2 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 2 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 4.83 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.95 |
| Logd | 2.183 |
| Logp | 4.114 |
| F (20%) | 0.001 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 98.71% |
| Vdss | 0.642 |
| Fu | 2.81% |
| Cyp1a2-inh | 0.307 |
| Cyp1a2-sub | 0.894 |
| Cyp2c19-inh | 0.96 |
| Cyp2c19-sub | 0.926 |
| Cl | 0.542 |
| T12 | 0.029 |
| H-ht | 0.79 |
| Dili | 0.986 |
| Roa | 0.18 |
| Fdamdd | 0.895 |
| Skinsen | 0.064 |
| Ec | 0.003 |
| Ei | 0.005 |
| Respiratory | 0.476 |
| Bcf | 0.738 |
| Igc50 | 4.378 |
| Lc50 | 5.119 |
| Lc50dm | 4.533 |
| Nr-ar | 0.003 |
| Nr-ar-lbd | 0.175 |
| Nr-ahr | 0.213 |
| Nr-aromatase | 0.024 |
| Nr-er | 0.694 |
| Nr-er-lbd | 0.089 |
| Nr-ppar-gamma | 0.486 |
| Sr-are | 0.689 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.007 |
| Sr-mmp | 0.867 |
| Sr-p53 | 0.238 |
| Vol | 522.674 |
| Dense | 1.066 |
| Flex | 0.296 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.345 |
| Synth | 3.337 |
| Fsp3 | 0.192 |
| Mce-18 | 87.613 |
| Natural product-likeness | -0.742 |
| Alarm nmr | 1 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |